Belief and action are different things entirely.
Across Australia and New Zealand, where the sun exacts its highest toll on human skin, a quiet contradiction has taken root in the workplace: organisations profess a duty of care they have not yet chosen to honour. A new report reveals that while most employers accept moral responsibility for protecting workers from ultraviolet harm, nearly half have never formally assessed the risk — and a quarter of board members do not yet recognise UV exposure as a workplace hazard at all. The gap between belief and action is not one of ignorance but of inertia, and in a landscape where skin cancer claims more lives than any other malignancy, that inertia carries a measurable human cost.
- The world's highest skin cancer rates sit inside a governance blind spot: 40% of ANZ organisations have never assessed workforce UV risk, even as 84% claim duty of care applies.
- Board-level misunderstanding is compounding the crisis — nearly one in four directors does not recognise ultraviolet exposure as a workplace hazard, leaving organisations legally exposed without knowing it.
- The financial logic is unambiguous: annual screening costs $100–200 per employee, while a single lost workday already exceeds that figure at $600 in productivity, and late-stage cancer treatment multiplies the loss across months of absence.
- Survival odds hinge on timing — Stage 0 melanoma carries a 98% ten-year survival rate, while the same disease caught at Stage 3 or 4 can fall to 24%, making early detection not a wellness gesture but a life-or-death decision.
- The report urges boards to reclassify skin checks as a formal WHS and ESG compliance obligation, backed by risk assessments, integrated diagnostic tools, and measurable KPIs — the infrastructure of accountability, not aspiration.
Australia and New Zealand are living inside a peculiar contradiction. Most employers — 84 percent — accept that skin cancer screening belongs within their duty of care to workers. Yet four in ten have never conducted a formal risk assessment, and nearly a quarter of board members do not recognise UV exposure as a workplace hazard at all. A new report, drawing on MoleMap's analysis of more than 48,000 workplace skin checks and a survey of 410 HR and wellbeing managers, has made the gap impossible to ignore.
Neither country operates a national screening programme, leaving the responsibility with employers — most of whom have not picked it up. The problem is not ignorance of skin cancer's severity. It is the failure to translate that awareness into action: the risk assessment never commissioned, the legal obligation never clarified, the monitoring programme never designed. Fifteen percent of respondents who felt confident in their ability to measure risk had never actually done so, creating a false sense of protection that exposes directors to real liability.
The financial case for intervention is straightforward. Screening costs between $100 and $200 per employee each year. A single missed workday costs $600 in lost productivity — already more than the annual prevention investment. New Zealand alone faces an estimated $648 million in productivity losses over 26 years without action. Advanced cases bring surgical appointments, extended recovery, and workers' compensation claims that dwarf any screening budget.
But the deeper argument is about survival. A precancerous lesion caught early can often be treated with topical cream. Melanoma detected at Stage 0 carries a 98 percent ten-year survival rate. The same cancer at Stage 3 or 4 drops to between 24 and 88 percent. The distance between those numbers is not measured in recovery time alone — it is the distance between a treatable condition and a terminal one.
The report calls on boards to stop treating skin checks as a wellness perk and begin treating them as a compliance requirement embedded in work health and safety law and ESG frameworks. Formal risk assessments, integrated diagnostic solutions, and clear performance indicators are the prescribed path forward. The tools exist. What the report is asking for is the decision to use them.
Australia and New Zealand face a peculiar crisis in workplace health: the gap between what employers say they believe and what they actually do. A new report on skin cancer screening across both countries has laid bare the contradiction. Eighty-four percent of organisations acknowledge that skin checks ought to fall under their duty of care to employees. Yet four in ten have never bothered to assess whether their workforce faces elevated risk. More troubling still, nearly a quarter of board members don't grasp that ultraviolet exposure constitutes a workplace hazard at all.
The research draws from two sources: MoleMap's analysis of more than 48,000 workplace skin checks and a survey of 410 human resources and wellbeing managers across Australia and New Zealand. What emerges is not ignorance so much as inertia. Organisations understand, in the abstract, that skin cancer matters. They know screening exists. But they have skipped the foundational step: the formal risk assessment, the clarity on their legal obligations, the decision about what adequate monitoring actually looks like.
Skin cancer remains the most common malignancy in both countries, and both consistently report the world's highest incidence rates. The burden is real and measurable. Yet neither nation operates a national screening programme. The responsibility falls to employers, and most have not picked it up.
The disconnect runs deeper than mere neglect. Fifteen percent of survey respondents who expressed confidence in their ability to measure risk had never actually conducted an assessment. This creates a false sense of security—and exposes directors to potential liability. The organisation believes itself protected when it is not.
The financial case for action is stark. New Zealand alone faces an estimated $648 million in productivity losses over 26 years without intervention. Australian figures would be proportionally higher given population size and incidence rates. The arithmetic is simple: screening costs $100 to $200 per employee annually. A single missed day of work, at $600 in lost productivity, already exceeds the annual screening cost. Advanced cases demand multiple surgical appointments, extended recovery periods, and weeks away from work—or workers' compensation claims that dwarf any prevention investment.
But the real difference lies in outcomes. Early detection transforms survival. A precancerous lesion caught in time can often be treated with topical cream, requiring minimal work disruption. Melanoma detected at Stage 0—melanoma in situ—carries a 98 percent ten-year survival rate. The same cancer caught at Stage 3 or 4 drops to between 24 and 88 percent. The difference between catching it early and catching it late is not a matter of months of recovery versus weeks. It is the difference between life and death, between a treatable condition and a terminal one.
The report calls on boards to reclassify skin checks not as a wellness perk but as a duty of care embedded in work health and safety obligations and environmental, social, and governance frameworks. Organisations are urged to conduct formal risk assessments, demand integrated diagnostic solutions from providers, and establish clear key performance indicators to track outcomes and demonstrate return on investment. The work is not mysterious. The tools exist. What remains is the decision to use them.
Citações Notáveis
At $600 per day in lost productivity, the annual cost of $100-200 per employee for screening is straightforward maths. Just 1-3 missed days cost more than yearly screening.— MoleMap whitepaper
A Conversa do Hearth Outra perspectiva sobre a história
Why would a board member not understand UV exposure as a workplace hazard? Isn't that basic knowledge?
You'd think so. But skin cancer screening isn't typically part of board-level health and safety training. It gets filed under wellness—a nice-to-have—rather than risk management. That's the governance gap.
So they're not denying the risk exists. They just haven't connected it to their legal obligations.
Exactly. Eighty-four percent believe duty of care applies. But belief and action are different things. Without a formal risk assessment, without someone assigned to it, it stays abstract.
The fifteen percent who claim confidence but never assessed—that's almost dangerous.
It is. They've created a false sense of compliance. If something happens, if an employee develops melanoma, the organisation can't point to a risk assessment. The liability exposure is real.
What would a formal assessment actually look like?
Understanding which roles have outdoor exposure, how much, for how long. Then deciding: do we screen everyone, or just high-risk groups? How often? What's our monitoring protocol? Most organisations haven't asked these questions.
And the survival rate difference between Stage 0 and Stage 3—that's the real story, isn't it?
That's everything. Ninety-eight percent survival versus 24 to 88 percent. That's not a health outcome. That's the difference between a treatable condition and a life-threatening one.